Long-term prognosis in patients with psoriasis

British Journal of Dermatology

Volumn 159, Issue SUPPL.2, 2008, Pages 2-9

  Gulliver, W ^a  

^a Newlab Clinical Research Inc   (Canada)

Author keywords

Biological agents; Cardiovascular risk; Comorbidity; Inflammation; Plaque psoriasis

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; LITHIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSORALEN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE CORONARY SYNDROME; ALCOHOL ABUSE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMORBIDITY; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; HELPER CELL; HUMAN; INFECTION RISK; KIDNEY DYSFUNCTION; LIVER TOXICITY; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; SIDE EFFECT; SKIN DEFECT; SKIN INFLAMMATION; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, PSORIATIC; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; PROGNOSIS; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49249102223     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2008.08779.x     Document Type: Review

References (85)

1. Griffiths CEM, Barker JWN. Pathogenesis and clinical features of psoriasis. Lancet 2007 370 : 263 71.
2. Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet 2007 370 : 272 84.
3. Gelfand JM, Weinstein R, Porter SB et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005 141 : 1537 41.
4. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005 352 : 1899 912.
5. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007 25 : 529 34.
6. Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003 4 : 833 42.
7. Herron MD, Hinckley M, Hoffman M et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005 141 : 1527 34.
8. Sterry W, Strober BE, Menter A et al. on behalf of the International Psoriasis Council. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007 157 : 649 55.
9. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006 298 : 309 18.
10. Madland TM, Apalset EM, Johannessen AE et al. Prevalence, disease manifestations, and treatment of psoriatic arthritis in Western Norway. J Rheumatol 2005 32 : 1918 22.
11. Zachariae H, Zachariae R, Blomqvist K et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002 82 : 108 13.
12. Gisondi P, Girolomoni G, Sampogna F et al. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005 15 : 279 83.
13. Gelfand JM, Gladman DD, Mease PJ et al. Epidemiology of psoriatic arthritis in population of the United States. J Am Acad Dermatol 2005 53 : 573.
14. Cohen MR, Reda DJ, Clegg DO. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 1999 26 : 1752 6.
15. Persson PG, Leijonmarck CE, Bernell O et al. Risk indicators for inflammatory bowel disease. Int J Epidemiol 1993 22 : 268 72.
16. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005 129 : 827 36.
17. Gelfand JM, Shin DB, Neimann AL et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006 126 : 2194 201.
18. Stern RS. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 2006 142 : 1132 5.
19. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998 134 : 1582 5.
20. Lundberg L, Johannesson M, Silverdahl M et al. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol 2000 80 : 430 4.
21. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999 41 : 401 7.
22. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005 64 (Suppl. 2 ii18 23.
23. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004 9 : 136 9.
24. Esposito M, Saraceno R, Giunta A et al. An Italian study on psoriasis and depression. Dermatology 2006 212 : 123 7.
25. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998 139 : 846 50.
26. Sommer DM, Jenisch S, Suchan M et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006 298 : 321 8.
27. Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005 125 : 61 7.
28. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 35.
29. Fortes C, Mastroeni S, Leffondre K et al. for the IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Study Group. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol 2005 141 : 1580 4.
30. Morse RM, Perry HO, Hurt RD. Alcoholism and psoriasis. Alcohol Clin Exp Res 1985 9 : 396 9.
31. Poikolainen K, Reunala T, Karvonen J et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ 1990 300 : 780 3.
32. Poikolainen K, Karvonen J, Pukkala E. Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis. Arch Dermatol 1999 135 : 1490 3.
33. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 1991 302 : 766 8.
34. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997 350 : 1097 9.
35. Gelfand JM, Dattani H, Margolis DJ. The UK General Practice Research Database. In : Pharmacoepidemiology (Strom BL, ed). New York, NY : John Wiley and Sons, 2005 337 46.
36. Krueger G, Ellis CN. Psoriasis - recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol 2005 53 : S94 100.
37. Hamminga EA, van der Lely AJ, Neumann HAM, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses 2006 67 : 768 73.
38. Eckel R, Grundy S, Zimmet P. The metabolic syndrome. Lancet 2005 365 : 1415 28.
39. Gisondi P, Tessari G, Conti A et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital based case-control study. Br J Dermatol 2007 157 : 68 73.
40. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004 33 : 351 75.
41. Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004 19 : 225 30.
42. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988 91 : 197 201.
43. Gelfand J, Neimann A, Shin D et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006 296 : 1735 41.
44. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 : 614 21.
45. Ludwig RJ, Herzog C, Rostock A et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007 156 : 271 6.
46. Chung CP, Avalos I, Raggi P, Stein CM. Atherosclerosis and inflammation: insights from rheumatoid arthritis. Clin Rheumatol 2007 26 : 1228 33.
47. Gelfand JM, Troxel AB, Lewis JD et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007 143 : 1493 9.
48. Gulliver W, Tomi Z, Alaghehbandan R. Prevalence of cardiovascular risk factors and other comorbidities among psoriasis patients. J Am Acad Dermatol 2007 56 (Suppl. 2 AB191.
49. Griffiths CEM, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004 150 (Suppl. 67 S11 23.
50. Griffiths CE, Clark CM, Chalmers RJ et al. A systematic review of treatments for severe psoriasis. Health Technol Assess Rep 2000 4 : 1 125.
51. Roenigk HH Jr., Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998 38 : 78 85.
52. Chong BF, Wong HK. Immunobiologics in the treatment of psoriasis. Clin Immunol 2007 123 : 129 38.
53. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 22.
54. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.
55. Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005 175 : 2721 9.
56. Lizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NFkappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005 124 : 1275 83.
57. Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003 112 : 1796 808.
58. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol 2007 57 : 347 54.
59. Pham T, Gossec L, Constantin A et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006 73 : 379 87.
60. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005 352 : 20 8.
61. McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004 363 : 2015 21.
62. Tikiz C, Utuk O, Pirildar T et al. Effects of angiotensin converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with long term rheumatoid arthritis. J Rheumatol 2005 32 : 2095 101.
63. Van Doornum S, McColl G, Wicks IP. Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis. Ann Rheum Dis 2004 63 : 1571 5.
64. Späh F. Inflammation in atherosclerosis and psoriasis: Common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008 vol 159 (Suppl. 2) : 10 17.
65. Choi HK, Hernan MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002 359 : 1173 7.
66. Michaud K, Wolfe F. Reduced mortality among RA patients treated with anti-TNF therapy and methotrexate. Ann Rheum Dis 2005 64 (Suppl. 3 87.
67. Prodanowich S, Ma F, Taylor JR et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005 52 : 262 7.
68. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with ciclosporin: a 5 y cohort study. J Invest Dermatol 2003 120 : 211 6.
69. Popa C, Netea MG, Radstake T et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005 64 : 303 5.
70. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 1213 18.
71. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007 56 : 2905 12.
72. Jacobsson LT, Turesson C, Nilsson JA et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007 66 : 670 5.
73. Smith CH, Anstey AV, Barker JNWN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 97.
74. Bongartz T, Sutton AJ, Sweeting MJ et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006 295 : 2275 85.
75. Geborek P, Bladstrom A, Turesson C et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005 64 : 699 703.
76. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007 66 (Suppl. 3 iii2 22.
77. Pay S for the Society for Research and Education in Rheumatology of Turkey. Risk of cancer in Turkish patients after treatment with TNF antagonists. Rheumatology (Oxf) 2008 47 : 548 9.
78. Saraceno R, Schipani C, Mazzotta A et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008 57 : 290 5.
79. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007 56 : 31. e1 15.
80. Lowes MA, Chamian F, Abello MV et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci USA 2005 102 : 19057 62.
81. Leonardi C, Menter A, Hamilton T et al. Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis. Br J Dermatol 2008 158 : 1107 16.
82. Zaghoul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004 140 : 408 14.
83. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008 58 : 443 6.
84. Buckingham BA, Sandborg CI. A randomized trial of methotrexate in newly diagnosed patients with type 1 diabetes mellitus. Clin Immunol 2000 96 : 86 90.
85. Tsankov N, Angelova I, Kazandjieva J. Drug-induced psoriasis. Recognition and management. Am J Clin Dermatol 2000 1 : 159 65.